Abstract:The emerging new lineages of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have marked a new phase of coronavirus disease 2019 (COVID-19). Understanding the recognition mechanisms of potent neutralizing monoclonal antibodies (NAbs) against the spike protein is pivotal for developing new vaccines and antibody drugs. Here, we isolated several monoclonal antibodies (MAbs) against the SARS-CoV-2 spike protein receptor-binding domain (S-RBD) from the B cell receptor repertoires of a SARS-CoV-2 convalescent. Among these MAbs, the antibody nCoV617 demonstrates the most potent neutralizing activity against authentic SARS-CoV-2 infection, as well as prophylactic and therapeutic efficacies against the human angiotensin-converting enzyme 2 (ACE2) transgenic mouse model in vivo . The crystal structure of S-RBD in complex with nCoV617 reveals that nCoV617 mainly binds to the back of the "ridge" of RBD and shares limited binding residues with ACE2. Under the background of the S-trimer model, it potentially binds to both "up" and "down" conformations of S-RBD. In vitro mutagenesis assays show that mutant residues found in the emerging new lineage B.1.1.7 of SARS-CoV-2 do not affect nCoV617 binding to the S-RBD. These results provide a new human-sourced neutralizing antibody against the S-RBD and assist vaccine development. IMPORTANCE COVID-19 is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic has posed a serious threat to global health and the economy, so it is necessary to find safe and effective antibody drugs and treatments. The receptor-binding domain (RBD) in the SARS-CoV-2 spike protein is responsible for binding to the angiotensin-converting enzyme 2 (ACE2) receptor. It contains a variety of dominant neutralizing epitopes and is an important antigen for the development of new coronavirus antibodies. The significance of our research lies in the determination of new epitopes, the discovery of antibodies against RBD, and the evaluation of the antibodies' neutralizing effect. The identified antibodies here may be drug candidates for the development of clinical interventions for SARS-CoV-2.

Identification of Human Single-Domain Antibodies Against SARS-CoV-2.

Fully Human Single-Domain Antibodies Against SARS-CoV-2

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

A Potent Neutralizing Human Antibody Reveals the N-terminal Domain of the Spike Protein of SARS-CoV-2 As a Site of Vulnerability

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Identification of SARS-CoV RBD-targeting Monoclonal Antibodies with Cross-Reactive or Neutralizing Activity Against SARS-CoV-2

Neutralizing Antibodies to SARS‐CoV‐2 Selected from a Human Antibody Library Constructed Decades Ago

Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies

Human IgG Neutralizing Monoclonal Antibodies Block SARS-CoV-2 Infection

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Structure-guided Affinity Maturation of a Novel Human Antibody Targeting the SARS-CoV-2 Nucleocapsid Protein

Expression of Receptor-binding Domain of SARS-CoV Spike Protein and Isolation of Highly Potent Neutralizing Antibody

Conserved Amino Acids W423 and N424 in Receptor-Binding Domain of SARS-CoV Are Potential Targets for Therapeutic Monoclonal Antibody.

Nanobodies against SARS-CoV-2 RBD from a Two-step Phage Screening of Universal and Focused Synthetic Libraries